Total Payments
$2,628
2024 Payments
$658.80
Companies
40
Transactions
143
Medicare Patients
1,918
Medicare Billing
$148,205
Payment Breakdown by Category
Food & Beverage$2,229 (84.8%)
Education$399.12 (15.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,229 | 137 | 84.8% |
| Education | $399.12 | 6 | 15.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $306.57 | 18 | $0 (2024) |
| Merck Sharp & Dohme LLC | $224.47 | 13 | $0 (2024) |
| Celgene Corporation | $203.63 | 12 | $0 (2024) |
| Amgen Inc. | $194.24 | 7 | $0 (2020) |
| Incyte Corporation | $193.54 | 5 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $151.62 | 4 | $0 (2019) |
| Janssen Biotech, Inc. | $126.07 | 7 | $0 (2024) |
| Astellas Pharma US Inc | $124.27 | 7 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $123.43 | 8 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $99.61 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $658.80 | 36 | PFIZER INC. ($111.72) |
| 2023 | $575.98 | 34 | PFIZER INC. ($130.83) |
| 2022 | $105.56 | 7 | Celgene Corporation ($43.08) |
| 2020 | $451.98 | 21 | Amgen Inc. ($115.47) |
| 2019 | $820.71 | 44 | Takeda Pharmaceuticals U.S.A., Inc. ($136.28) |
| 2018 | $15.34 | 1 | Takeda Pharmaceuticals U.S.A., Inc. ($15.34) |
All Payment Transactions
143 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $16.29 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $18.24 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: Oncology | ||||||
| 10/08/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $18.80 | General |
| Category: ONCOLOGY | ||||||
| 09/26/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $17.24 | General |
| Category: Hematology | ||||||
| 09/24/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $19.57 | General |
| Category: ONCOLOGY | ||||||
| 09/16/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $25.68 | General |
| Category: ONCOLOGY | ||||||
| 09/10/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $22.86 | General |
| 08/26/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $22.54 | General |
| Category: Oncology | ||||||
| 08/08/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $14.57 | General |
| Category: Oncology | ||||||
| 08/06/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $13.14 | General |
| Category: Oncology | ||||||
| 07/30/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $17.39 | General |
| Category: Oncology | ||||||
| 07/23/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $14.92 | General |
| Category: Oncology | ||||||
| 07/22/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: ONCOLOGY | ||||||
| 07/18/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $22.50 | General |
| Category: ONCOLOGY | ||||||
| 07/15/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: Oncology | ||||||
| 07/11/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $15.28 | General |
| Category: Oncology | ||||||
| 07/08/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $15.51 | General |
| Category: ONCOLOGY | ||||||
| 06/11/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 05/09/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: Oncology | ||||||
| 04/23/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $21.43 | General |
| Category: Oncology | ||||||
| 04/22/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: Oncology | ||||||
| 04/15/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $19.57 | General |
| Category: ONCOLOGY | ||||||
| 04/11/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $17.00 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 40 | 1,597 | 12,035 | $539,022 | $136,071 |
| 2022 | 12 | 321 | 406 | $45,370 | $12,133 |
Total Patients
1,918
Total Services
12,441
Medicare Billing
$148,205
Procedure Codes
52
All Medicare Procedures & Services
52 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 167 | 487 | $112,984 | $45,124 | 39.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 32 | 138 | $48,576 | $13,203 | 27.2% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 11 | 5,200 | $20,800 | $7,160 | 34.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 54 | 54 | $19,278 | $6,530 | 33.9% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 176 | 608 | $46,208 | $6,293 | 13.6% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 11 | 770 | $11,550 | $4,738 | 41.0% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 13 | 61 | $10,675 | $4,714 | 44.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 187 | 604 | $37,448 | $4,590 | 12.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 27 | 34 | $10,642 | $4,542 | 42.7% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 17 | 28 | $21,856 | $4,214 | 19.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 29 | 58 | $10,324 | $3,487 | 33.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 49 | 58 | $10,730 | $3,177 | 29.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 28 | 31 | $10,447 | $3,062 | 29.3% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 39 | 103 | $13,208 | $2,814 | 21.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 13 | 48 | $7,776 | $2,280 | 29.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 27 | 196 | $16,856 | $2,248 | 13.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 45 | 169 | $8,788 | $1,771 | 20.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 17 | $4,352 | $1,523 | 35.0% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 73 | 113 | $13,108 | $1,498 | 11.4% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 64 | 89 | $7,921 | $1,315 | 16.6% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 24 | 53 | $6,890 | $1,257 | 18.2% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 16 | 26 | $20,295 | $1,172 | 5.8% |
| 83550 | Iron binding capacity | Office | 2023 | 74 | 113 | $10,509 | $960.60 | 9.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 66 | 112 | $3,024 | $940.80 | 31.1% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 11 | 14 | $2,912 | $878.64 | 30.2% |
About Dr. Sukriti Kamboj, M.D
Dr. Sukriti Kamboj, M.D is a Internal Medicine healthcare provider based in Greenville, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/02/2012. The National Provider Identifier (NPI) number assigned to this provider is 1134475650.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sukriti Kamboj, M.D has received a total of $2,628 in payments from pharmaceutical and medical device companies, with $658.80 received in 2024. These payments were reported across 143 transactions from 40 companies. The most common payment nature is "Food and Beverage" ($2,229).
As a Medicare-enrolled provider, Kamboj has provided services to 1,918 Medicare beneficiaries, totaling 12,441 services with total Medicare billing of $148,205. Data is available for 2 years (2022–2023), covering 52 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine, Internal Medicine
- Location Greenville, NC
- Active Since 08/02/2012
- Last Updated 12/21/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1134475650
Products in Payments
- KEYTRUDA (Biological) $213.23
- IBRANCE (Drug) $114.43
- VELCADE (Drug) $111.49
- Enhertu (Drug) $98.51
- XTANDI (Drug) $95.99
- OPDIVO (Biological) $95.01
- ERLEADA (Drug) $86.30
- REBLOZYL (Biological) $80.96
- CABOMETYX (Drug) $75.04
- Lenvima (Drug) $55.49
- Padcev (Drug) $48.31
- Pomalyst (Drug) $46.02
- Revlimid (Drug) $44.29
- INLYTA (Drug) $41.53
- BRUKINSA (Drug) $40.96
- JAKAFI (Drug) $40.56
- Xtandi (Drug) $40.48
- ALIMTA (Drug) $38.69
- KISQALI (Drug) $35.32
- BOSULIF (Drug) $34.93
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Greenville
Stephen Dyar, Md, MD
Internal Medicine — Payments: $381,835
Internal Medicine $381,835
Dr. John Catanzaro, Md, MD
Internal Medicine — Payments: $331,996
Internal Medicine $331,996
Bhumika Patel, M.d, M.D
Internal Medicine — Payments: $208,547
Internal Medicine $208,547
Dr. Thomas Gallaher, M.d, M.D
Internal Medicine — Payments: $208,355
Internal Medicine $208,355
Bruce Gray, D.o, D.O
Internal Medicine — Payments: $166,102
Internal Medicine $166,102
Dr. Mark Purcell, Do, DO
Internal Medicine — Payments: $135,587
Internal Medicine $135,587